Dental Tribune India

Johnson & Johnson single-shot COVID-19 vaccine receives FDA approval

By Rajeev Chitguppi, Dental Tribune South Asia
February 27, 2021

A key advisory group of the Food and Drug Administration experts, known as the Vaccines and Related Biological Products Advisory Committee, has recommended the Johnson & Johnson coronavirus vaccine's approval on Friday, 26 February. This will pave the way for the authorization of this vaccine and its availability at the earliest.

In a long discussion session, the Johnson & Johnson scientists argued that their single-shot vaccine was 66 percent effective at preventing moderate to severe COVID-19 and 85% effective against severe illness.

This FDA approval was expected because Johnson and Johnson's vaccine has met all the FDA criteria established last year for vaccine authorization, including a large-scale trial that proved the safety and efficacy and the company's ability to manufacture the COVID-19 vaccine consistently and safely.

The Johnson & Johnson vaccine is a viral vector vaccine that makes use of a harmless adenovirus viral vector – and replaces a small fragment of its genetic code with the genes of SARS-CoV-2 spike protein.

Leave a Reply

Your email address will not be published. Required fields are marked *

© 2021 - All rights reserved - Dental Tribune International